Teijin reported a net loss of ￥1.63 billion ($21 million) in the fscal frst quarter ended June 30, 2012, compared with a net proft of ￥6.27 billion in year-ago quarter. Sales decreased 8%, to ￥174.3 billion, due to slowing economic growth in Europe and the U.S., which hampered sales in the company's aramid fbers and other materials businesses, and also due to the impact of the revision of drug reimbursement prices on results in the healthcare business segment, Teijin says.
展开▼
